文献速递泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

插入缺失衍生的肿瘤特异性新抗原与免疫原性表型:泛癌分析

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
PubMed 文献 · Lancet Oncol · 2017-07-07

该泛癌分析基于癌症基因组图谱5777例、19种实体瘤的全外显子测序数据,比较插入缺失突变的比例与数量,并在两个独立数据集中重复部分结果。肾细胞癌的插入缺失比例(0.12)和数量最高(p<2.2×10^-16);插入缺失来源新抗原对高亲和力结合物的富集为非同义单核苷酸变异突变的3倍,对突变特异性结合的富集为9倍;在三个黑色素瘤队列中,移码插入缺失计数与检查点抑制剂应答显著相关(p=4.7×10^-4)。

要点

  • 肾细胞癌的插入缺失突变比例(0.12)和数量在泛癌队列中最高(p<2.2×10^-16)。
  • 插入缺失来源新抗原对高亲和力结合物的富集为非同义单核苷酸变异突变的3倍,对突变特异性结合的富集为9倍。
  • 在三个独立黑色素瘤队列中,移码插入缺失计数与检查点抑制剂应答显著相关(p=4.7×10^-4)。

核心结论

  • 肾细胞癌在泛癌中具有最高的插入缺失突变比例和数量。
  • 证据提示插入缺失是高度免疫原性的突变类别,可触发新抗原丰度增加和更高的突变结合特异性。

研究设计与样本

  • 分析癌症基因组图谱中5777例、19种癌症类型的实体瘤全外显子测序数据。
  • 在泛癌队列中比较插入缺失的比例和数量,部分结果在两个独立数据集中重复。
  • 按突变类型进行计算机模拟肿瘤特异性新抗原预测,并在392例肾透明细胞癌病例中结合RNA测序分析比较患者亚组的免疫基因表达。
  • 在四个检查点抑制剂数据集中评估插入缺失负荷与治疗应答的关联。

主要发现

  • 肾细胞癌的插入缺失突变比例(0.12)和数量在泛癌队列中最高(p<2.2×10^-16),超过所有其他受检癌症类型插入缺失突变中位比例的两倍以上。
  • 插入缺失突变对高亲和力结合物的富集为非同义单核苷酸变异突变的3倍。
  • 插入缺失突变来源的新抗原对突变特异性结合的富集为非同义单核苷酸变异来源新抗原的9倍。
  • 在肾透明细胞癌队列中,突变特异性新抗原的存在与抗原呈递基因上调相关,并与CD8阳性表达所测T细胞活化相关(r=0.78)。
  • 在三个独立黑色素瘤队列中,移码插入缺失计数与检查点抑制剂应答显著相关(p=4.7×10^-4)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype. METHODS: We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas. We compared the proportion and number of indels across the cohort, with a subset of results replicated in two independent datasets. We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer analysis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune gene expression across patient subgroups. Associations between indel burden and treatment response were assessed across four checkpoint inhibitor datasets. FINDINGS: We observed renal cell carcinomas to have the highest proportion (0·12) and number of indel mutations across the pan-cancer cohort (p<2·2 × 10-16), more than double the median proportion of indel mutations in all other cancer types examined. Analysis of tumour-specific neoantigens showed that enrichment of indel mutations for high-affinity binders was three times that of non-synonymous SNV mutations. Furthermore, neoantigens derived from indel mutations were nine times enriched for mutant specific binding, as compared with non-synonymous SNV derived neoantigens. Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen presentation genes, which correlated (r=0·78) with T-cell activation as measured by CD8-positive expression. Finally, analysis of checkpoint inhibitor response data revealed frameshift indel count to be significantly associated with checkpoint inhibitor response across three separate melanoma cohorts (p=4·7 × 10-4). INTERPRETATION: Renal cell carcinomas have the highest pan-cancer proportion and number of indel mutations. Evidence suggests indels are a highly immunogenic mutational class, which can trigger an increased abundance of neoantigens and greater mutant-binding specificity. FUNDING: Cancer Research UK, UK National Institute for Health Research (NIHR) at the Royal Marsden Hospital National Health Service Foundation Trust, Institute of Cancer Research and University College London Hospitals Biomedical Research Centres, the UK Medical Research Council, the Rosetrees Trust, Novo Nordisk Foundation, the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017. PMID: 28694034. doi:10.1016/S1470-2045(17)30516-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。